PTPRA encodes a receptor protein tyrosine phosphatase that serves as a key regulator of multiple cellular signaling pathways with significant clinical implications. The protein functions as a transmembrane phosphatase that directly interacts with and dephosphorylates receptor tyrosine kinases, particularly RET, thereby regulating GDNF-dependent signaling and inhibiting oncogenic RET variants like MEN2A 1. PTPRA amplifies transforming growth factor-β (TGF-β)-dependent profibrotic signaling in lung fibroblasts through both canonical and noncanonical pathways, promoting pulmonary fibrosis development 2. The phosphatase also contributes to fibroproliferative responses following acute lung injury, with genetic deficiency providing protection against fibrotic outcomes 3. In disease contexts, PTPRA shows significant clinical relevance. Loss-of-function studies reveal its involvement in neurodevelopmental processes, with Ptpra-deficient mice exhibiting schizophrenia-like behaviors including sensorimotor gating defects and altered myelination gene expression 4. Human genetic studies support associations with neuropsychiatric disorders, identifying rare variants potentially increasing susceptibility to schizophrenia and autism spectrum disorders 5. Additionally, PTPRA regulation through microRNAs affects hepatic fibrosis 6 and atherosclerosis progression 7, highlighting its broader pathological significance across multiple organ systems.